Three-target, multi-year collaboration includes
the development of bispecific antibodies to treat sight-threatening
complication of type 1 and 2 diabetes
AbCellera (Nasdaq: ABCL) and Angios GmbH (Angios) announced
today that they have entered into a multi-year, multi-target
collaboration to facilitate the discovery of monoclonal and
bispecific antibodies for vascular diseases of the eye. AbCellera
will use its full stack, AI-powered antibody discovery platform to
generate panels of antibodies for up to three Angios-selected
targets to address diabetic retinopathy.
“Through this collaboration, Angios can focus on advancing their
unique scientific insights for treating blindness in diabetes,
rather than on establishing and scaling internal antibody discovery
capabilities,” said Carl Hansen, Ph.D., CEO and President of
AbCellera. “We are excited to work closely with Angios to start
their programs without delay, including identifying bispecific
antibodies against diabetic retinopathy, and moving them forward at
maximum speed.”
Diabetic retinopathy, which is a complication of type 1 and 2
diabetes, is caused by chronic hyperglycemia and is the leading
cause of preventable visual impairment and blindness in working-age
adults. Patients with diabetes who have an increased risk of
developing retinopathy include those with comorbid hypertension and
dyslipidemia.1,2
“As a young biotech, we have to use our resources
efficiently to maximize the development of novel therapeutics for
growing numbers of patients affected by this life-altering
disease,” said Gregor Wick, Ph.D., CEO of Angios. “Our partnership
with AbCellera will greatly improve our ability to realize our
ambitious goals to accelerate therapeutic development so patients
can get meaningful new therapies as soon as possible.”
“There are 400 million patients with diabetes, and the numbers
are rapidly growing,” said Josef Penninger, Ph.D., Chairman of
Angios. “Changes in blood vessels are the major cause for diabetic
symptoms such as kidney failure, heart attacks, non-healing wounds,
and also blindness. There is an enormous unmet medical need to
develop novel therapies for these patients.”
Under the terms of the agreement, Angios will have the rights to
develop and commercialize therapeutic products resulting from the
collaboration. AbCellera will receive equity and research fees and
is eligible for milestone payments and royalties based on the
development and commercialization of antibodies generated by
AbCellera under this collaboration.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, visit www.abcellera.com.
About Angios
Angios GmbH (Angios) is a biotechnology company specializing in
developing therapeutics for vascular diseases with a vision of
improving standard of care for diabetic retinopathy. Founded in
2021 and based in Innsbruck, Austria, Angios strives to develop new
treatments for challenging vascular diseases by pursuing
pre-identified targets for diabetic retinopathy and by leveraging
the vascular organoid model developed in the laboratories of our
founders. For more information, visit www.angios-bio.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
1 Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet.
2010;376(9735):124-136. doi:10.1016/S0140-6736(09)62124-3
2 Ghamdi AHA. Clinical Predictors of Diabetic Retinopathy
Progression; A Systematic Review. Curr Diabetes Rev.
2020;16(3):242-247. doi:10.2174/1573399815666190215120435
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210506005458/en/
AbCellera Inquiries: Media: Jessica Yingling;
media@abcellera.com, +1(236) 521-6774 Business Development: Kevin
Heyries; bd@abcellera.com, +1(604) 559-9005 Investor Relations:
ir@abcellera.com; +1(778) 729-9116
Angios Inquiries: office@angios-bio.com
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024